Demethylzeylasteral (T-96) treatment ameliorates mice lupus nephritis accompanied by inhibiting activation of NF- κB Pathway

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Hu, Qiongyi ^a   Yang, Chunxin ^a   Wang, Qiang ^a   Zeng, Haiying ^a   Qin, Wanzhang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CD68 ANTIGEN; CYCLOOXYGENASE 2; DEMETHYLZEYLASTERAL; DOUBLE STRANDED DNA ANTIBODY; HERBACEOUS AGENT; I KAPPA B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 23; KANG LANG CHUANG SAN; PLANT MEDICINAL PRODUCT; PREDNISONE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PTGS2 PROTEIN, MOUSE; RELA PROTEIN, MOUSE; TRITERPENE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; FEMALE; INFLAMMATORY CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEINURIA; ANIMAL; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; ISOLATION AND PURIFICATION; KIDNEY; LUPUS NEPHRITIS; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYTOTHERAPY; PLANT ROOT; PRECLINICAL STUDY; RANDOMIZATION; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TRIPTERYGIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; FEMALE; I-KAPPA B KINASE; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; LUPUS NEPHRITIS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MOLECULAR STRUCTURE; NF-KAPPA B; PHYTOTHERAPY; PLANT ROOTS; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TRIPTERYGIUM; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941900155     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133724     Document Type: Article

References (49)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008; 358:929-939. doi: 10. 1056/NEJMra071297 PMID: 18305268.
2. Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol. 2006; 18:468-475. PMID: 16896284.
3. Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013; 65:2154-2160. doi: 10. 1002/art.38006 PMID: 23754671.
4. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011; 365:2110-2121. doi: 10.1056/NEJMra1100359 PMID: 22129255.
5. Sahu R, Bethunaickan R, Singh S, Davidson A. Structure and function of renal macrophages and dendritic cells from lupus-prone mice. Arthritis Rheumatol. 2014; 66:1596-1607. doi: 10.1002/art.38410 PMID: 24866269.
6. Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol. 2008; 180:1938-1947. PMID: 18209092.
7. Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol. 2011; 186:4994-5003. doi: 10.4049/jimmunol.1003010 PMID: 21411733.
8. Liu H, Diao C, Wu C, Xia L, Duan H, Fang F, et al. Anti-macrophage-derived chemokine antibody relieves murine lupus nephritis. Rheumatol Int. 2011; 31:1459-1464. doi: 10.1007/s00296-010-1499-x PMID: 20473504.
9. Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, et al. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci USA. 2010; 107:3012-3017. doi: 10.1073/pnas.0914902107 PMID: 20133703.
10. Wong ET, Tergaonkar V. Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2009; 116:451-465.
11. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26:203-234. doi: 10.1101/gad.183434.111 PMID: 22302935.
12. Kalergis AM, Iruretagoyena MI, Barrientos MJ, Gonzalez PA, Herrada AA, Leiva ED, et al. Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus. Immunology. 2009; 128:e306-e314. doi: 10.1111/j.1365-2567.2008.02964.x PMID: 19016912.
13. Tsai PY, Ka SM, Chang JM, Chen HC, Shui HA, Li CY, et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med. 2011; 51:744-754. doi: 10.1016/j.freeradbiomed.2011.05. 016 PMID: 21641991.
14. Lee SW, Park YB, Yang J, Park KH, Lee SK, Choi KH, et al. Attenuation of nephritis in lupus-prone mice by thalidomide. Rheumatology (Oxford). 2012; 51:2131-2140.
15. Jiang T, Tian F, Zheng H, Whitman SA, Lin Y, Zhang Z, et al. Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-kappaB-mediated inflammatory response. Kidney Int. 2014; 85:333-343. doi: 10.1038/ki.2013.343 PMID: 24025640.
16. Ghosh S, Hayden MS. Celebrating 25 years of NF-κB research. Immunol Rev. 2012; 246:5-13. doi: 10. 1111/j.1600-065X.2012.01111.x PMID: 22435544.
17. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry. 2007; 68:732-766. PMID: 17250858.
18. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: A double-blind, placebo-controlled study. Arthritis Rheum. 2002; 46:1735-1743. PMID: 12124856.
19. Ji W, Li J, Lin Y, Song YN, Zhang M, Ke Y, et al. Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii. Clin Rheumatol. 2010; 29:1067-1072. doi: 10.1007/s10067-010- 1497-0 PMID: 20563618.
20. Tao X, Fan F, Hoffmann V, Gao CY, Longo NS, Zerfas P, et al. Effective therapy for nephritis in (NZB x NZW)F1 mice with triptolide and tripdiolide, the principal active components of the Chinese herbal remedy Tripterygium wilfordii Hook F. Arthritis Rheum. 2008; 58:1774-1783. doi: 10.1002/art.23513 PMID: 18512813.
21. Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U. Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol. 2012; 74:424-436. doi: 10.1111/j. 1365-2125.2012.04221.x PMID: 22348323.
22. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: A randomized trial. Ann Intern Med. 2009; 151:229-240, W49-W51. PMID: 19687490.
23. Xu W, Lin Z, Yang C, Zhang Y, Wang G, Xu X, et al. Immunosuppressive effects of demethylzeylasteral in a rat kidney transplantation model. Int Immunopharmacol. 2009; 9:996-1001. doi: 10.1016/j.intimp. 2009.04.007 PMID: 19383554.
24. Zhou ZL, Yang YX, Ding J, Li YC, Miao ZH. Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep. 2012; 29:457-475. doi: 10.1039/c2np00088a PMID: 22270059.
25. Ho LJ, Chang WL, Chen A, Chao P, Lai JH. Differential immunomodulatory effects by Tripterygium wilfordii Hook f-derived refined extract PG27 and its purified component PG490 (triptolide) in human peripheral blood T cells: potential therapeutics for arthritis and possible mechanisms explaining in part Chinese herbal theory "Junn-Chenn-Zuou-SS". J Transl Med. 2013; 11:294. doi: 10.1186/1479-5876- 11-294 PMID: 24256769.
26. Shi X. Medical Laboratory Animal Science. Xi'an: Shaanxi Science and Technology Press; 1989.
27. Zhang L, Yang N, Wang S, Huang B, Li F, Tan H, et al. Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. Lupus. 2011; 20:667-677. doi: 10.1177/0961203310393262 PMID: 21183557.
28. Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant. 2005; 20:96- 104. PMID: 15546891.
29. Zhang L, Fu XH, Yu Y, Shui RH, Li C, Zeng HY, et al. Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis. Lab Invest. 2015; 95:65-77. doi: 10.1038/labinvest.2014.135 PMID: 25384123.
30. Zheng L, Sinniah R, Hsu SI. Pathogenic role of NF-kappaB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. J Histochem Cytochem. 2008; 56:517-529. doi: 10.1369/jhc.7A7368. 2008 PMID: 18285351.
31. Zheng L, Sinniah R, Hsu SI. In situ glomerular expression of activated NF-kappaB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Arch. 2006; 448:172-183. PMID: 16205945.
32. Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010; 20:87-103. PMID: 21133840.
33. Bethunaickan R, Sahu R, Liu Z, Tang YT, Huang W, Edegbe O, et al. Anti-tumor necrosis factor alpha treatment of interferon-alpha-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation. Arthritis Rheum. 2012; 64:3399-3408. doi: 10.1002/art.34553 PMID: 22674120.
34. Yung S, Cheung KF, Zhang Q, Chan TM. Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis. Clin Dev Immunol. 2013; 2013:317682. doi: 10.1155/2013/317682 PMID: 24171032.
35. Abd-Elkareem MI, Al TH, Khamis OA, Abdellatif SS, Hussein MR. Increased urinary levels of the leukocyte adhesion molecules ICAM-1 and VCAM-1 in human lupus nephritis with advanced renal histological changes: preliminary findings. Clin Exp Nephrol. 2010; 14:548-557. doi: 10.1007/s10157-010- 0322-z PMID: 20714774.
36. Kang HK, Ecklund D, Liu M, Datta SK. Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. Arthritis Res Ther. 2009; 11:R59. doi: 10.1186/ar2682 PMID: 19405952.
37. Zhang L, Bertucci AM, Smith KA, Xu L, Datta SK. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Arthritis Rheum. 2007; 56:4132-4141. PMID: 18050205.
38. Menke J, Rabacal WA, Byrne KT, Iwata Y, Schwartz MM, Stanley ER, et al. Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J Am Soc Nephrol. 2009; 20:2581-2592. doi: 10.1681/ASN.2009050499 PMID: 19926892.
39. Okamoto A, Fujio K, van Rooijen N, Tsuno NH, Takahashi K, Tsurui H, et al. Splenic phagocytes promote responses to nucleosomes in (NZB x NZW) F1 mice. J Immunol. 2008; 181:5264-5271. PMID: 18832681.
40. Zhu J, Liu X, Xie C, Yan M, Yu Y, Sobel ES, et al. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest. 2005; 115:1869-1878. PMID: 15951839.
41. Holdsworth SR, Tipping PG. Leukocytes in glomerular injury. Semin Immunopathol. 2007; 29:355-374. PMID: 17938927.
42. Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. Int J Biol Sci. 2014; 10:520-529. doi: 10.7150/ijbs.8879 PMID: 24910531.
43. Cai Y, Zhang W, Xiong S. Mannose-binding lectin blunts macrophage polarization and ameliorates lupus nephritis. PLoS One. 2013; 8:e62465. doi: 10.1371/journal.pone.0062465 PMID: 23626823.
44. Berthier CC, Bethunaickan R, Gonzalez-Rivera T, Nair V, Ramanujam M, Zhang W, et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol. 2012; 189:988-1001. doi: 10.4049/jimmunol.1103031 PMID: 22723521.
45. Zhao J, Zhang H, Huang Y, Wang H, Wang S, Zhao C, et al. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation. Int Immunopharmacol. 2013; 17:116-122. doi: 10.1016/j.intimp.2013.05.027 PMID: 23770281.
46. Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: Are we approaching journey's end? Rheumatology (Oxford). 2007; 46:1052-1056.
47. Raz E, Brezis M, Rosenmann E, Eilat D. Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J Immunol. 1989; 142:3076-3082. PMID: 2785132.
48. Okamura M, Kanayama Y, Amastu K, Negoro N, Kohda S, Takeda T, et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis. 1993; 52:14- 20. PMID: 8427508.
49. Ehrenstein MR, Katz DR, Griffiths MH, Papadaki L, Winkler TH, Kalden JR, et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 1995; 48:705-711. PMID: 7474655.